Dr. Zelenetz on the Impact of Rituximab in Lymphoma

Andrew D. Zelenetz, MD, PhD
Published: Monday, Jan 14, 2013

Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab (Rituxan) has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

As more is known about the mutations involved in cancer, research will gradually begin to shift more toward exploring targeted therapies. Despite the push toward newer therapies, older agents have made major improvements in outcomes for patients, Zelenetz highlights.

As an example, Zelenetz notes that targeted therapies have been used in non-Hodgkin and B-cell lymphomas since rituximab (Rituxan) was first approved. Rituximab, a CD20-directed monoclonal antibody, has made a huge impact in the treatment of lymphoma and has saved more lives than any other targeted therapy, Zelenetz believes. Overall, this agent has greatly changed outcomes for patients with B-cell and non-Hodgkin lymphoma.

In general the success of rituximab has served as an important proof of concept by demonstrating the superior results that can be generated by directly targeting the tumor.

Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab (Rituxan) has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

As more is known about the mutations involved in cancer, research will gradually begin to shift more toward exploring targeted therapies. Despite the push toward newer therapies, older agents have made major improvements in outcomes for patients, Zelenetz highlights.

As an example, Zelenetz notes that targeted therapies have been used in non-Hodgkin and B-cell lymphomas since rituximab (Rituxan) was first approved. Rituximab, a CD20-directed monoclonal antibody, has made a huge impact in the treatment of lymphoma and has saved more lives than any other targeted therapy, Zelenetz believes. Overall, this agent has greatly changed outcomes for patients with B-cell and non-Hodgkin lymphoma.

In general the success of rituximab has served as an important proof of concept by demonstrating the superior results that can be generated by directly targeting the tumor.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x